Cargando…

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Eso, Yuji, Takeda, Haruhiko, Taura, Kojiro, Takai, Atsushi, Takahashi, Ken, Seno, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534657/
https://www.ncbi.nlm.nih.gov/pubmed/34677270
http://dx.doi.org/10.3390/curroncol28050352
_version_ 1784587604348370944
author Eso, Yuji
Takeda, Haruhiko
Taura, Kojiro
Takai, Atsushi
Takahashi, Ken
Seno, Hiroshi
author_facet Eso, Yuji
Takeda, Haruhiko
Taura, Kojiro
Takai, Atsushi
Takahashi, Ken
Seno, Hiroshi
author_sort Eso, Yuji
collection PubMed
description Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relatively well tolerated; however, factors that can predict its response have not yet been reported. Thus, we aimed to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) could predict the therapeutic response in patients with HCC treated with Atezo/Bev therapy. Methods: We analyzed the course of 40 patients with HCC who received Atezo/Bev therapy at our hospital and attempted to identify pretreatment factors that could predict response by comparing those who achieved disease control with those who did not. Results: The pretreatment NLR value in patients who achieved disease control was significantly lower than that in patients with disease progression (2.47 vs. 4.48, p = 0.013). Using the optimal NLR cut-off value for predicting response (3.21) determined by receiver operating characteristic curve analysis, patients with NLR ≤ 3.21 had significantly better progression-free survival than those with NLR > 3.21 (p < 0.0001), although there were no significant differences in liver function or tumor-related background factors between the two groups. Conclusions: The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC.
format Online
Article
Text
id pubmed-8534657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85346572021-10-23 Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma Eso, Yuji Takeda, Haruhiko Taura, Kojiro Takai, Atsushi Takahashi, Ken Seno, Hiroshi Curr Oncol Article Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relatively well tolerated; however, factors that can predict its response have not yet been reported. Thus, we aimed to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) could predict the therapeutic response in patients with HCC treated with Atezo/Bev therapy. Methods: We analyzed the course of 40 patients with HCC who received Atezo/Bev therapy at our hospital and attempted to identify pretreatment factors that could predict response by comparing those who achieved disease control with those who did not. Results: The pretreatment NLR value in patients who achieved disease control was significantly lower than that in patients with disease progression (2.47 vs. 4.48, p = 0.013). Using the optimal NLR cut-off value for predicting response (3.21) determined by receiver operating characteristic curve analysis, patients with NLR ≤ 3.21 had significantly better progression-free survival than those with NLR > 3.21 (p < 0.0001), although there were no significant differences in liver function or tumor-related background factors between the two groups. Conclusions: The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC. MDPI 2021-10-14 /pmc/articles/PMC8534657/ /pubmed/34677270 http://dx.doi.org/10.3390/curroncol28050352 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eso, Yuji
Takeda, Haruhiko
Taura, Kojiro
Takai, Atsushi
Takahashi, Ken
Seno, Hiroshi
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
title Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
title_full Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
title_fullStr Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
title_full_unstemmed Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
title_short Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
title_sort pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534657/
https://www.ncbi.nlm.nih.gov/pubmed/34677270
http://dx.doi.org/10.3390/curroncol28050352
work_keys_str_mv AT esoyuji pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma
AT takedaharuhiko pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma
AT taurakojiro pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma
AT takaiatsushi pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma
AT takahashiken pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma
AT senohiroshi pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma